Master Luck

Master Luck (H.K.) Limited is a biotechnology company that serves as the holding entity for the divested Greater China operations of I-Mab. Following a strategic restructuring in 2024, the company assumed control of a comprehensive pipeline of innovative biologics focused on oncology and autoimmune diseases, as well as a state-of-the-art manufacturing facility in Hangzhou. Its portfolio features several late-stage clinical assets, including felzartamab for multiple myeloma and eftansomatropin alfa for pediatric growth hormone deficiency. Master Luck operates as a fully integrated biopharmaceutical company with capabilities spanning from early-stage discovery to commercial-scale production. The company is led by I-Mab’s founder, Dr. Jingwu Zang, and is positioned to advance its therapeutic candidates through the Chinese regulatory landscape.